Phase II study of metronomic chemotherapy with bevacizumab for recurrent glioblastoma after progression on bevacizumab therapy - Wikidata - wikimedia - TriplyDB

Phase II study of metronomic chemotherapy with bevacizumab for recurrent glioblastoma after progression on bevacizumab therapy

Phase II study of metronomic chemotherapy with bevacizumab for recurrent glioblastoma after progression on bevacizumab therapy

http://www.wikidata.org/entity/Q35008766

about

The Role of End-of-Life Issues in the Design and Reporting of Cancer Clinical Trials: A Structured Literature Review Combinations of vascular endothelial growth factor pathway inhibitors with metronomic chemotherapy: Rational and current status Effect of angiogenesis inhibitor bevacizumab on survival in patients with cancer: a meta-analysis of the published literature.Validation of the prognostic Heidelberg re-irradiation score in an independent mono-institutional patient cohort.Curcumin inhibits vasculogenic mimicry through the downregulation of erythropoietin-producing hepatocellular carcinoma-A2, phosphoinositide 3-kinase and matrix metalloproteinase-2.Antiangiogenic therapy for glioblastoma: current status and future prospects.Recurrence pattern analysis after re-irradiation with bevacizumab in recurrent malignant glioma patients Phase 2 study of carboplatin, irinotecan, and bevacizumab for recurrent glioblastoma after progression on bevacizumab therapy.Lessons from anti-vascular endothelial growth factor and anti-vascular endothelial growth factor receptor trials in patients with glioblastoma.Dose-dense temozolomide: is it still promising?A review of VEGF/VEGFR-targeted therapeutics for recurrent glioblastoma.Outcome after bevacizumab clinical trial therapy among recurrent grade III malignant glioma patients.Bevacizumab continuation beyond initial bevacizumab progression among recurrent glioblastoma patients.Phase II trial of continuous low-dose temozolomide for patients with recurrent malignant glioma.A randomized phase II trial of standard dose bevacizumab versus low dose bevacizumab plus lomustine (CCNU) in adults with recurrent glioblastoma Etoposide-Bevacizumab a new strategy against human melanoma cells expressing stem-like traits.Bevacizumab in glioblastoma multiforme.Incidence and management of gastrointestinal perforation from bevacizumab in advanced cancers.Metronomic chemotherapy for cancer treatment: a decade of clinical studies.Update on bevacizumab and other angiogenesis inhibitors for brain cancer.Bevacizumab for glioblastoma-a promising drug or not?Targeted therapy in gliomas.Metronomics: towards personalized chemotherapy?Current evidence of temozolomide and bevacizumab in treatment of gliomas.Molecularly targeted therapies for recurrent glioblastoma: current and future targets.Incorporation of biomarkers in phase II studies of recurrent glioblastoma.ReACT Phase II trial: a critical evaluation of the use of rindopepimut plus bevacizumab to treat EGFRvIII-positive recurrent glioblastoma.Bevacizumab in recurrent glioblastoma: five informative patient scenarios.Use of bevacizumab in recurrent glioblastoma.Can bevacizumab prolong survival for glioblastoma patients through multiple lines of therapy?Alisertib demonstrates significant antitumor activity in bevacizumab resistant, patient derived orthotopic models of glioblastoma.Clinical outcomes in recurrent glioblastoma with bevacizumab therapy: An analysis of the literature.Neurosurgery Concepts: Key perspectives on Traumatic Brain Injury, New Treatments for Glioblastoma, Hemicraniectomy for Extensive Middle-Cerebral-Artery Stroke, Minimally Invasive Spine Surgery and Lumbar Epidural Injections for Radiculopathy.Tumor dynamics in response to antiangiogenic therapy with oral metronomic topotecan and pazopanib in neuroblastoma xenografts.Metabolic alterations underlying Bevacizumab therapy in glioblastoma cells.Salvage stereotactic radiosurgery for recurrent gliomas with prior radiation therapy.Role for cytotoxic chemotherapy in patients with recurrent glioblastoma progressing on bevacizumab: a retrospective case series.Cullin1 regulates proliferation, migration and invasion of glioma cells.Addition of lomustine for bevacizumab-refractory recurrent glioblastoma.Adverse event grading following CTCAE v3.0 underestimates hypertensive side effects in patients with glioma treated with Bevacizumab.

P2860

Q26795613-4AF22694-9BB7-4DAE-A0AD-32CEAFFCACDA Q27001560-47A86031-369E-4E85-80A4-6F39E5787F17 Q31060162-D85F9BBA-970F-4A17-A21E-7257D113FA3C Q33851320-81283D8A-FC7B-45E2-8A9F-C194CEEC9687 Q34141672-FDB761C1-F698-4000-9D4B-3FF7B140E409 Q34523319-3944D622-0AD0-4820-B886-53DE795FDDFB Q35018538-46DAD95C-66F8-4C5A-B6FC-CED3F3A15093 Q35172814-3680401F-3725-4EB2-B47F-8695CDF76657 Q35895174-F39D3A3D-BD9F-4C5E-8DF2-AA4C8300BFE7 Q35943654-75E7EDAE-B922-4240-AE0B-0ABE1BA63217 Q36103026-5E953DF0-4095-42BD-AC23-204BD9C10045 Q36112002-36F44224-9B5C-469F-805A-E010C347B432 Q36385285-D695D7AE-E33C-4106-8474-CAFC04605679 Q36544101-D4429449-9291-46A5-BC57-82C5D5F7BA2E Q37253358-53B5247D-1A8D-4981-9FD3-2E50CAB9F04E Q37588253-E89BB3AD-4DEF-4D8A-911A-47747342ADCB Q37965628-564D87D1-0684-4F2F-83DF-0C1BC17684C1 Q38005357-F090D980-2965-449E-BC23-B8BF6D32F956 Q38087885-C8891261-0D4A-4697-A172-E08C3CB70726 Q38106370-73F0A4D8-A89C-41AF-A354-2694084E9F66 Q38161401-4FCE5C79-3EEA-48C3-B38B-F9E5326E1A35 Q38186656-2B8A2247-E4EF-4470-900B-B74F10FEF080 Q38218923-2F7923FC-4BC8-4994-A925-3590BB3FFB3E Q38230650-701629FE-CC62-4A90-866C-CDDE8FE96E40 Q38272728-DB910938-C7A6-4B31-84EA-0F530263A8C4 Q38298124-5253A95F-A849-494A-B2C2-43867F423828 Q38398440-A757C312-E0B3-466F-B699-E9A9384F8928 Q38409696-73CCD83E-0B67-4870-8377-019FD07E3EE6 Q38438668-C599F916-0419-4918-ADDA-35CE34E30683 Q39173162-BA372C0D-5099-4097-ADF5-84CD436AD7AB Q39211981-B44BA937-BAD7-44C4-B4BA-F7DA47C89075 Q39436924-E30897AB-E0C6-4549-A2DE-298B1931B416 Q41865686-7E6AD519-EC9E-441E-B27D-C0F354FB7E32 Q41912972-0FC70BE2-2B1F-42FD-BE89-0B49B71C9340 Q47114557-59CD438E-8179-4276-B5C4-2A5FA1BD5EBF Q47805151-BD8199AC-F58A-4CE3-982F-07712B97C24B Q48365671-BE43105A-A994-4C9F-A489-A03F596964A3 Q48556580-DD25A8DF-B0F0-4CC2-B30D-1ABECD9144F6 Q48766164-1D7D52AE-58F3-4BB2-AAB6-90F32D8E70DE Q49066603-0233F90C-2D49-4E24-B262-3F2817DD27D0

P2860

Phase II study of metronomic chemotherapy with bevacizumab for recurrent glioblastoma after progression on bevacizumab therapy

http://www.wikidata.org/entity/Q35008766

description

2010 nî lūn-bûn

@nan

2010 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Phase II study of metronomic c ...... ression on bevacizumab therapy

@ast

Phase II study of metronomic c ...... ression on bevacizumab therapy

@en

type

label

Phase II study of metronomic c ...... ression on bevacizumab therapy

@ast

Phase II study of metronomic c ...... ression on bevacizumab therapy

@en

prefLabel

Phase II study of metronomic c ...... ression on bevacizumab therapy

@ast

Phase II study of metronomic c ...... ression on bevacizumab therapy

@en

P1433

Q35008766-36BC7093-DD3B-43FB-A2DE-6EDBCE3B935B

P1476

Q35008766-55E3CFE4-AC25-4508-A2C5-99E8AFD5D18A

P2093

Q35008766-031B925B-296D-4B3C-B079-B7F2292F7CC7

Q35008766-1CF3A453-C67C-48D7-9213-4FE342E2A2E6

Q35008766-30E305AB-BD21-4BAC-A346-3E7C11689544

Q35008766-3FC22CBC-EB5E-4959-8603-17AC0A2E4DCE

Q35008766-A327BF34-76FE-4736-8BD1-C1CAAF8A72D3

Q35008766-AAC68E22-7082-442E-AE77-C5B52CF8CF6B

Q35008766-DF8B135F-BE36-4787-ABDC-D3506025C0C2

P2860

Q35008766-07C1AD17-ED88-455C-B519-9A2113B434C8

Q35008766-0B7CA300-A790-432C-855E-15BCC54A468B

Q35008766-1059A5B7-3117-422F-B938-5465904BD732

Q35008766-10B4CE98-1211-43C9-8279-7DFFD68FC463

Q35008766-13E4A752-7EA2-4200-AD6A-DAEB777C3A44

Q35008766-181D6E33-98B5-420C-9556-F21E03CCD4C3

Q35008766-18F138C9-35E5-4CC1-A738-736111B5ED44

Q35008766-1BD176DF-1491-49A0-850B-0D47681DFDCD

Q35008766-1BE7F214-E7A6-41B8-B43E-3F302E51373C

Q35008766-1CDAB32D-B9F4-4F24-A872-AE5B468B030E

P2888

Q35008766-27E305F2-86BD-4D3A-B939-A09450B76F4A

P304

Q35008766-6C73AF5E-2BD4-4804-A9D8-8F7D36F49729

P31

Q35008766-7C3E2F70-C40E-4FB2-B388-749E7292842E

P356

Q35008766-71B33A1D-769F-447E-8734-74C897BBC071

P433

Q35008766-21B0BAED-D5DE-4105-A932-62319B8B0626

P478

Q35008766-9A4E72BE-E7D2-4931-9DB9-82C8A388BFCF

P50

Q35008766-035B28EA-E844-4092-A053-E8B116B1F19C

Q35008766-2BC1899D-E96A-448B-884A-D47CF56864E7

Q35008766-3CA78EE8-93C3-40F3-9367-B552D221C839

Q35008766-412DDC42-E90C-428E-9B27-7B51E1AAB82F

Q35008766-8986DDF2-8AB5-4DD3-B5B8-F9757CAC0BAA

Q35008766-D94BEA93-E10D-44A2-BFAD-FF87DA1C66FE

P577

Q35008766-2E1D6964-5E99-4E7F-8412-5AD21D52A61F

P5875

Q35008766-62D455D6-AA9F-4578-8FA3-FF68C9EB8185

P698

Q35008766-CC1DF852-62A7-4549-B4AC-C7D617AAEF6D

P921

Q35008766-4591B47B-8108-453E-8DE1-8AA5E56E1829

Q35008766-98ED95C7-EB36-4F3E-B2BD-4CD17AD3855C

P932

Q35008766-562BCAFD-4F66-4FEA-A578-66A1D57D397A

P356

S11060-010-0403-6

P1433

Journal of Neuro-Oncology

P1476

Phase II study of metronomic c ...... ression on bevacizumab therapy

@en

P2093

James E Herndon

http://www.w3.org/2001/XMLSchema#string

James J Vredenburgh

http://www.w3.org/2001/XMLSchema#string

Jennifer Marcello

http://www.w3.org/2001/XMLSchema#string

Jeremy N Rich

http://www.w3.org/2001/XMLSchema#string

John Sampson

http://www.w3.org/2001/XMLSchema#string

Katherine Peters

http://www.w3.org/2001/XMLSchema#string

Stevie Threatt

http://www.w3.org/2001/XMLSchema#string

P2860

Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity

Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma

Interim analyses for randomized clinical trials: the group sequential approach

Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer

Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma

Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer

Phase II study of metronomic chemotherapy for recurrent malignant gliomas in adults.

AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients.

Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence.

Marked inactivation of O6-alkylguanine-DNA alkyltransferase activity with protracted temozolomide schedules

P2888

s11060-010-0403-6

P304

371-379

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S11060-010-0403-6

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

103

http://www.w3.org/2001/XMLSchema#string

P50

Henry Seth Friedman

Annick Desjardins

Sridharan Gururangan

David A Reardon

Roger E McLendon

P577

2010-09-19T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

46307324

http://www.w3.org/2001/XMLSchema#string

P698

20853132

http://www.w3.org/2001/XMLSchema#string

P921

P932

3102515

http://www.w3.org/2001/XMLSchema#string